School of Chinese Medicine
Interference of the binding of programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) has become a new inspiring immunotherapy for resisting cancers. To date, the FDA has approved two PD-1 monoclonal antibody drugs against cancer as well as a monoclonal antibody for PD-L1. More PD-1 and PD-L1 monoclonal antibody drugs are on their way in clinical trials. In this review, we focused on the mechanism of the PD-1/PD-L1 signaling pathway and the monoclonal antibodies (mAbs) against PD-1 and PD-L1, which were approved by the FDA or are still in clinical trials. And also presented is the prospect of the PD-1/PD-L1 immune checkpoint blockade in the next generation of immunotherapy.
Immunotherapy, PD-1 (Programmed cell death protein 1), PD-L1 (Programmed death-ligand 1), monoclonal antibodies (mAbs)
Source Publication Title
International Journal of Molecular Sciences
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
Link to Publisher's Edition
Li, Y., Li, F., Jiang, F., Lv, X., Zhang, R., Lu, A., & Zhang, G. (2016). A mini-review for cancer immunotherapy: Molecular understanding of PD-1/PD-L1 pathway & translational blockade of immune checkpoints. International Journal of Molecular Sciences, 17 (7), 1151. https://doi.org/10.3390/ijms17071151